Rossari Biotech Ltd
Rossari Biotech Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Rossari Biotech targets mid-teens percentage growth in overall business revenue, with an annual growth rate around 15% (Page 4, 6). - Ethoxylation capacity expansion expected to be commissioned by Q2 FY26, supporting growth in key segments (Page 4). - HPPC (Home and Personal Care) business anticipated to grow in low double digits (~10%) in FY26, with some mid-teens growth possible due to new non-EO products (Page 6). - Consumer and Institutional businesses grew 67% YoY to Rs. Consumer businesses expected to be profitable by FY27, with expansion fully online and higher Ethylene Oxide (EO) availability (Sunil Chari).
From Rossari Biotech Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Rossari Biotech targets mid-teens percentage growth in overall business revenue, with an annual growth rate around 15% (Page 4, 6).
- Ethoxylation capacity expansion expected to be commissioned by Q2 FY26, supporting growth in key segments (Page 4).
- HPPC (Home and Personal Care) business anticipated to grow in low double digits (~10%) in FY26, with some mid-teens growth possible due to new non-EO products (Page 6).
- Consumer and Institutional businesses grew 67% YoY to Rs. 299 crore in FY25 and expected to scale meaningfully in coming years, aiming for profitability by FY27 (Pages 4, 13).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Rossari Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ongoing CAPEX focused on Ethoxylation capacity expansion expected to be operational by Q2 FY26.
- Additional CAPEX of Rs. 192 crore approved for phased expansions at subsidiaries Unitop Chemicals, Tristar Intermediates (Rs. 97 crore), and Rossari Biotech (Rs. 95 crore), to be commissioned by Q4 FY26.
- New expansions emphasize non-Ethylene Oxide (EO) products, backward integration including Esters and Monomers, and new chemistries in the Mellitic space.
- Investments include scaling up biosurfactant production with a large fermenter addition.
- R&D expansion underway, including a new center in Mumbai and increased staffing for innovation and future product development.
- Aim to enhance production capabilities, supply reliability, operational efficiency, and support scalable, sustainable growth.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Rossari Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Rossari Biotech Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹685 Cr, net profit ₹46 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Rossari Biotech Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Chemicals & Petrochemicals this season
- Atul Ltd (Q4 FY25)
Consolidated revenue from operations for 2024-25: ₹5,583 cr, 18% increase YoY from ₹4,726 cr in 2023-24 (Page 36). Key concall takeaways from Atul Ltd's Q4…
- Vidhi Specialty Food Ingredients Ltd (Q4 FY25)
109.5 Crs, up 40.2% YoY (from Rs. Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Chemcon Speciality Chemicals Ltd (Q4 FY25)
54.9 Crs, down 8% YoY from Rs. Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Valiant Organics Ltd (Q4 FY25)
Q4-FY25 revenue from operations (consolidated) was INR 2,038 million, a 15.3% year-on-year (YoY) increase from INR 1,768 million in Q4-FY24 (Page 12 and 10)…
Frequently Asked Questions
What were Rossari Biotech Ltd Q4 FY25 results?
Rossari Biotech targets mid-teens percentage growth in overall business revenue, with an annual growth rate around 15% (Page 4, 6). - Ethoxylation capacity expansion expected to be commissioned by Q2 FY26, supporting growth in key segments (Page 4). - HPPC (Home and Personal Care) business anticipated to grow in low double digits (~10%) in FY26, with some mid-teens growth possible due to new non-EO products (Page 6). - Consumer and Institutional businesses grew 67% YoY to Rs. Consumer businesses expected to be profitable by FY27, with expansion fully online and higher Ethylene Oxide (EO) availability (Sunil Chari).
What is Rossari Biotech Ltd share price analysis?
Rossari Biotech Ltd currently shows a neutral. The stock trades at a P/E of 18.5 with a market cap of ₹2,786 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rossari Biotech Ltd planning capital expenditure?
Ongoing CAPEX focused on Ethoxylation capacity expansion expected to be operational by Q2 FY26.
Keep Rossari Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.